Share ownership AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:13 20/06/2025 BST			5-day change	1st Jan Change
10,392.00 ^GBX	-1.52%		-5.41%	-0.73%

06-02	ASTRAZENECA : Buy rating from JP Morgan	ZD
06-02	UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains	RE

Share class: AstraZeneca PLC

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,550,581,134	1,498,095,796 ( 96.62 %)	0	96.62 %

Major shareholders: AstraZeneca PLC

Name	Equities	%	Valuation
Wellington Management Co. LLP 4.2 %	65,120,892	4.2 %	9 414 M p
The Vanguard Group, Inc. 3.746 %	58,087,000	3.746 %	8 397 M p
BlackRock Investment Management (UK) Ltd. 3.599 %	55,810,709	3.599 %	8 068 M p
Investor AB (Investment Company) 3.327 %	51,587,810	3.327 %	7 458 M p
Norges Bank Investment Management 1.998 %	30,984,000	1.998 %	4 479 M p
BlackRock Fund Advisors 1.983 %	30,748,000	1.983 %	4 445 M p
Capital Research & Management Co. (World Investors) 1.74 %	26,972,817	1.74 %	3 899 M p
SSgA Funds Management, Inc. 1.085 %	16,826,000	1.085 %	2 432 M p
Capital Research & Management Co. (Global Investors) 1.049 %	16,262,736	1.049 %	2 351 M p
BlackRock Advisors LLC 1.016 %	15,748,000	1.016 %	2 277 M p
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
T. Rowe Price International Ltd. 1.841 %	57,086,881	1.841 %	4 158 M p
PRIMECAP Management Co. 1.311 %	40,661,485	1.311 %	2 961 M p
Wellington Trust Co., NA 1.149 %	35,630,680	1.149 %	2 595 M p
Merrill Lynch International 1.026 %	31,833,015	1.026 %	2 318 M p
Capital Research & Management Co. (International Investors) 1.009 %	31,285,560	1.009 %	2 279 M p
Fidelity Management & Research Co. LLC 0.7444 %	23,085,277	0.7444 %	1 681 M p
Fiduciary Trust Company International 0.6804 %	21,101,993	0.6804 %	1 537 M p
Fisher Asset Management LLC 0.6502 %	20,165,459	0.6502 %	1 469 M p
Eaton Vance Management 0.5085 %	15,768,536	0.5085 %	1 148 M p
Sanders Capital LLC 0.4859 %	15,068,986	0.4859 %	1 097 M p
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Caixa DTVM SA 0.002856 %	265,823	0.002856 %	3 M p

Breakdown by shareholder type

Institutional	53.45%
Other	1.64%
Individuals	0.04%
Governments	0.02%
Wärtsilä Oyj Abp	0.01%
Avolta AG	0.01%
Principal Financial Group, Inc.	0.01%
Unknown	44.82%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	22.88%
United Kingdom	16.64%
Sweden	4.46%
Norway	2.25%
Luxembourg	1.18%
Switzerland	1.01%
France	1%
Netherlands	0.95%
Germany	0.87%
Singapore	0.59%
Canada	0.54%
Japan	0.35%
South Korea	0.29%
Hong Kong	0.24%
Denmark	0.23%
Spain	0.23%
Bahamas	0.22%
Ireland	0.2%
Malaysia	0.19%
Italy	0.16%
Finland	0.15%
Australia	0.15%
Kuwait	0.11%
Belgium	0.04%
South Africa	0.04%
United Arab Emirates	0.04%
Individuals	0.04%
Bermuda	0.04%
Austria	0.02%
Thailand	0.02%
Portugal	0.01%
New Zealand	0.01%
Cyprus	0.01%

Based on 1000 largest holdings

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

07-29 - Q2 2025 Earnings Release

More about the company